TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06439082: A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) Versus Placebo, With or Without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent an

Sponsor: Novartis Pharmaceuticals · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 354 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$11,173,128

Rescue Site Savings

+$7,354,464

Unlock Full NCT06439082 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06439082 Rescue Dossier →